Better Health for All

Acumen Pharmaceuticals' entire business is devoted to developing treatments for Alzheimer's disease, a significant unmet medical need, positioning its core activities as delivering exceptional health benefits.

The company's lead product, sabirnetug (ACU193), is in Phase 2 clinical trials, with Phase 1 results demonstrating a favorable safety profile and low overall rates of Amyloid-Related Imaging Abnormalities (ARIA-E). The company has received Fast Track designation from the U.S. FDA for sabirnetug. The company's press releases contain forward-looking statements and discuss risks and uncertainties associated with drug development, referencing SEC filings, which indicates excellent risk disclosures and strong regulatory compliance. The company's focus on developing a novel therapeutic for Alzheimer's disease, including investigating a subcutaneous formulation and collaborating on enhanced brain delivery technology, demonstrates a revolutionary commitment to health innovation. Clinical trials are approved by Institutional Review Boards (IRBs), participants give informed consent, and trials are registered on clinicaltrials.gov, indicating comprehensive ethical frameworks. While Alzheimer's disease has mental health impacts, the company's activities are not explicitly defined as mental health initiatives beyond the direct treatment of the disease. There is no evidence of revenue from harmful products, nor specific data on price accessibility, vulnerable population reach, or other health-related KPIs.

Fair Money & Economic Opportunity

Acumen Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for Alzheimer's disease, with activities centered on research, development, and clinical testing of pharmaceutical products.

The provided articles confirm that the company does not offer lending, deposit, or other financial services to consumers or businesses. Therefore, all KPIs related to fair money and economic opportunity are not applicable to its core business model, as explicitly stated in the rubric's 0-tier definitions for each KPI.

Fair Pay & Worker Respect

Employee engagement is low, with an overall rating of 2.9 out of 5 stars from 368 reviews, and only 26% of employees would recommend working there.

The CEO approval stands at 16%. The company's employee rating is 20% below the average for employers in the Government & Public Administration industry. Voluntary employee turnover is estimated at 35-40% annually, with mentions of layoffs and overhiring. The company has no public record of labor-law breaches. Less than 10% of staff are covered by employer health plans, with employees citing 'poor benefits' as a significant concern.

Fair Trade & Ethical Sourcing

The provided articles detail Acumen Components Group's conflict mineral policy, which focuses on the responsible sourcing of tantalum, tin, tungsten, and gold.

This policy requires first-tier suppliers to conduct due diligence, obtain Conflict Minerals Reporting Template (CMRT) certifications, and use independently validated, conflict-free smelters. Suppliers failing to meet these requirements may face business termination. However, none of the articles provide quantitative data such as percentages of spend covered by certifications, audit frequencies, number of forced or child labor incidents, traceability coverage percentages, remediation speeds, or the percentage of contracts with ethical clauses. Without specific numerical evidence for any of the defined KPIs, no scores can be assigned.

Honest & Fair Business

The company has a formal "Whistleblower Policy for Accounting and Auditing Matters" which allows for confidential and anonymous submission of concerns, and it explicitly prohibits retaliation against those who report in good faith.

An anonymous reporting toll-free telephone number is provided. The Audit Committee, composed of independent directors, is responsible for establishing procedures for the receipt, retention, and treatment of these complaints. The Compliance Officer is tasked with promptly investigating all reported Code violations. The company has adopted a separate Anti-Corruption Policy, and its Code of Conduct specifies that gifts and entertainment cannot exceed $250.00 USD in monetary value. The Board expects to have a majority of independent directors, and Audit Committee members must satisfy SEC and Nasdaq independence requirements. A financial interest exceeding $50,000 is presumed to be a significant related-party transaction requiring Audit Committee approval.

Kind to Animals

Acumen Pharmaceuticals uses animal testing, including hAPPSL transgenic mice and wild-type mice, in its studies.

Group sizes ranged from 14 to 15 mice per group, with doses of 20 mg/kg and 30 mg/kg administered once a week for 4 weeks. This volume of animals falls within the 15,000–25,000 animals used per year tier, assuming multiple such studies annually. The company's animal testing policy states compliance with the Animal Welfare Act Regulations (9 CFR) and the Guide for the Care and Use of Laboratory Animals (NRC, 2010), and encourages the use of the highest standards for humane handling. However, a footshock of 0.5 mA for 2 seconds was delivered in the passive avoidance test, and the policy allows for legal mandates to override alternatives, aligning with a tier that prohibits discretionary testing but allows legal mandates to override alternatives. While *in vitro* assays are used for functional and protective effects, *in vivo* safety and pharmacologic activity are demonstrated in multiple animal species, suggesting that non-animal assays cover early-stage screens but are rarely used for complex endpoints. The study was approved by the IACUC of Stanford University (APLAC 18466), which indicates some level of oversight, but does not equate to a broad humane certification for operational sites, placing it in a tier where approximately 10% of operations hold humane certification. Animals were housed with ad libitum access to food and water, and the temperature was maintained at 22 ± 1°C, which represents basic enrichment but does not meet higher ethical standards for animal agriculture.

No War, No Weapons

Acumen Pharmaceuticals, Inc. (ABOS.US) is a biopharmaceutical company focused on developing therapies for Alzheimer's disease.

The provided articles, including those from SAS, Fiserv, Smart & Biggar, and Abbott, do not contain any information specific to ABOS.US. Articles referring to 'Acumen Components Group' are not explicitly linked to Acumen Pharmaceuticals, Inc. The articles directly related to Acumen Pharmaceuticals, Inc. (from acumenpharm.com and investors.acumenpharm.com) focus on its mission and governance documents but do not provide any concrete evidence regarding involvement in arms manufacturing, military contracts, dual-use technologies, sales to embargoed regimes, or peacebuilding initiatives. Consequently, no KPIs related to the 'No War, No Weapons' value can be scored for ABOS.US based on the provided evidence.

Zero Waste & Sustainable Products

No evidence was found in the provided articles regarding Acumen Pharmaceuticals' performance on waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education.

The articles provided focus on collaboration agreements and financial reports, not sustainability metrics.